{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:05:50Z","timestamp":1790240750110,"version":"4.1.0"},"reference-count":73,"publisher":"Institute of Electrical and Electronics Engineers (IEEE)","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"name":"European Research Council","award":["647573"],"award-info":[{"award-number":["647573"]}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IEEE Trans. Biomed. Eng."],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1109\/tbme.2020.2982749","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T22:20:14Z","timestamp":1589408414000},"page":"3296-3306","source":"Crossref","is-referenced-by-count":15,"title":["Model-Based Optimal AML Consolidation Treatment"],"prefix":"10.1109","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0316-7055","authenticated-orcid":false,"given":"Felix","family":"Jost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Schalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8059-5021","authenticated-orcid":false,"given":"Daniela","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Dohner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0283-9075","authenticated-orcid":false,"given":"Sebastian","family":"Sager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"263","reference":[{"key":"ref73","first-page":"1","article-title":"Optimization and clinical decision support","volume":"104","author":"sager","year":"2018"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.beha.2016.10.008","article-title":"Is there justification for 4 cycles of consolidation therapy in AML","volume":"29","author":"schlenk","year":"2016","journal-title":"Best Practice & Research Clinical Haematology"},{"key":"ref71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109892","article-title":"Dose schedule optimization and the pharmacokinetic driver of neutropenia","volume":"9","author":"patel","year":"2014","journal-title":"PLoS ONE"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.6004\/jnccn.2017.7044","article-title":"Controversies regarding use of myeloid growth factors in leukemia","volume":"15","author":"poston","year":"2017","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1093\/bioinformatics\/btz063","article-title":"Modeling cell proliferation in human acute myeloid leukemia xenografts","volume":"35","author":"nobile","year":"0","journal-title":"Bioinformatics"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21115-4"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2010.11.007"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1051\/mmnp\/20127199"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-5564(96)00086-7"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0006-3495(76)85772-4","article-title":"A mathematical model of the chemotherapeutic treatment of acute myeloblastic leukemia","volume":"16","author":"rubinow","year":"1976","journal-title":"Biophys J"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/ni1080","article-title":"Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity","volume":"5","author":"hope","year":"2004","journal-title":"Nat'l Immunology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nm0797-730"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<59::AID-CNCR9>3.0.CO;2-H","article-title":"High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias","volume":"79","author":"kern","year":"1997","journal-title":"Cancer"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204540","article-title":"Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia","volume":"14","author":"jost","year":"2019","journal-title":"PLoS ONE"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: A consensus document from the european leukemianet mrd working party","volume":"131","author":"schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mpo.2950100706","article-title":"Relationship between plasma ARA-C and intracellular ARA-CTP pools under conditions of continuous infusion and high-dose ARA-C treatment","volume":"10","author":"rustum","year":"1982","journal-title":"Medical and Pediatric Oncology"},{"key":"ref61","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127457","article-title":"Predicting minimal residual disease in acute myeloid leukemia through stochastic modeling of clonality","author":"dinh","year":"2019","journal-title":"Blood"},{"key":"ref63","first-page":"5952","article-title":"Relationship of 1-$\\beta$-d-arabinofuranosylcytosine in plasma to 1-$\\beta$-d-arabinofuranosylcytosine 5?-triphosphate levels in leukemic cells during treatment with high-dose 1-$\\beta$-d-arabinofuranosylcytosine","volume":"45","author":"liliemark","year":"1985","journal-title":"Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0249-y"},{"key":"ref64","article-title":"Exploring the antitumor mechanism of high-dose cytarabine through the metabolic perturbations of ribonucleotide and deoxyribonucleotide in human promyelocytic leukemia hl-60 cells","volume":"22","author":"li","year":"2017","journal-title":"Molecules"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1158\/1078-0432.CCR-08-0807","article-title":"Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling","volume":"14","author":"shochat","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/0006-2952(73)90342-0","article-title":"Pharmacokinetics of 1-$\\beta$-d-arabinofuranosylcytosine (ARA-C) deamination in several species","volume":"22","author":"dedrick","year":"1973","journal-title":"Biochemical Pharmacology"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10107-005-0679-z","article-title":"Extending scope of robust optimization: Comprehensive robust counterparts of uncertain problems","volume":"107","author":"ben-tal","year":"2006","journal-title":"Math Program"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bcp.13504","article-title":"Pharmacokinetic&#x2013;pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia","volume":"84","author":"melhem","year":"2018","journal-title":"British Journal of Clinical Pharmacology"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<105::AID-AJH3>3.0.CO;2-W"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-015-0272-3"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/10428199309064256","article-title":"G-CSF in the treatment of acute myeloid leukemia: Is it safe?","volume":"11","author":"ohno","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.2004.05285.x","article-title":"Criteria for defining a complete remission in acute myeloid leukaemia revisited. an analysis of patients treated in hovon-sakk co-operative group studies","volume":"128","author":"greef","year":"2005","journal-title":"British Journal of Haematology"},{"key":"ref1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"d\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922008191"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-0987(00)00219-0"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702641"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.059121"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.150"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2540-1"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4682-9-32"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cep.2006.06.021","article-title":"An overview of simultaneous strategies for dynamic optimization","volume":"46","author":"biegler","year":"2007","journal-title":"Chem Eng Process"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s10107-004-0559-y"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by ngs before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"thol","year":"2018","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001425"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-468348"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2019.0043"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1093\/bioinformatics\/btr431","article-title":"Genssi: A software toolbox for structural identifiability analysis of biological models","volume":"27","author":"chi?","year":"2011","journal-title":"Bioinformatics"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.0030189"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10928-018-9569-x","article-title":"Structural identifiability for mathematical pharmacology: Models of myelosuppression","volume":"45","author":"evans","year":"2018","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109623"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"111v","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"klastersky","year":"2016","journal-title":"Ann Oncology"},{"key":"ref11","first-page":"e8845-1","article-title":"Clinical implications, safety, efficacy of recombinant human granulocyte colony-stimulating factors and pegylated equivalent","volume":"10","author":"bolis","year":"2013","journal-title":"Epidemiol Biostatist Public Health"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1200\/JCO.1988.6.4.583","article-title":"Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia","volume":"6","author":"cassileth","year":"1988","journal-title":"J Clin Oncology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tvjl.2006.08.001","article-title":"Granulocyte and granulocyte macrophage colony-stimulating factors as therapy in human and veterinary medicine","volume":"174","author":"fern\u00e1ndez-var\u00f3n","year":"2007","journal-title":"The Veterinary Journal"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1007\/s11095-014-1429-9","article-title":"Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling","volume":"31","author":"quartino","year":"2014","journal-title":"Pharmaceutical Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011534529622"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2008.09.043"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2165\/11318090-000000000-00000"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010376966"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006288731"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2165\/11586040-000000000-00000"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B","volume":"331","author":"mayer","year":"1994","journal-title":"New England J Med"},{"key":"ref3","article-title":"National cancer institute. common terminology criteria for adverse events (CTCAE) v5.0","year":"2017"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0395-y"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.45"},{"key":"ref8","author":"hoffbrand","year":"2016","journal-title":"Postgraduate Haematology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ajh.23622","article-title":"Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: Randomized controlled trial","volume":"89","author":"paul","year":"2014","journal-title":"American Journal of Hematology"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s12532-018-0139-4"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907","article-title":"Filgrastim (R-methug-CSF): the first 10 years","volume":"88","author":"welte","year":"1996","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","article-title":"Model of chemotherapy-induced myelosuppression with parameter consistency across drugs","volume":"20","author":"friberg","year":"2002","journal-title":"J Clin Oncology"},{"key":"ref45","doi-asserted-by":"crossref","DOI":"10.1137\/1.9780898719383","author":"biegler","year":"2010","journal-title":"Nonlinear Programming Concepts Algorithms and Applications to Chemical Processes"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1124\/jpet.117.240309","article-title":"Semimechanistic bone marrow exhaustion pharmacokinetic\/pharmacodynamic model for chemotherapy-induced cumulative neutropenia","volume":"362","author":"henrich","year":"2017","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-06-0815","article-title":"Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs","volume":"12","author":"kloft","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1109\/TBME.2014.2313226"},{"key":"ref41","article-title":"Modelling and optimisation based drug delivery systems for the treatment of acute myeloid leukemia (AML)","author":"pefani","year":"2013"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/bloodadvances.2016003194","article-title":"Quantification and three-dimensional microanatomical organization of the bone marrow","volume":"1","author":"nombela-arrieta","year":"2017","journal-title":"Blood Advances"},{"key":"ref43","author":"lichtman","year":"2006","journal-title":"Williams Hematology"}],"container-title":["IEEE Transactions on Biomedical Engineering"],"original-title":[],"link":[{"URL":"http:\/\/xplorestaging.ieee.org\/ielx7\/10\/9264772\/09093109.pdf?arnumber=9093109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T02:06:32Z","timestamp":1696125992000},"score":1,"resource":{"primary":{"URL":"https:\/\/ieeexplore.ieee.org\/document\/9093109\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":73,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1109\/tbme.2020.2982749","relation":{},"ISSN":["0018-9294","1558-2531"],"issn-type":[{"value":"0018-9294","type":"print"},{"value":"1558-2531","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}